Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Daylong Actinica** is a broad-spectrum sunscreen lotion (SPF 50+) specifically formulated for patients at high risk of non-melanoma skin cancer, including those with actinic keratosis, a history of skin cancer, photodamaged skin from chronic UV exposure, or immunosuppression (e.g., organ transplant recipients, autoimmune diseases). It features a unique combination of photostable chemical and hybrid UV filters—**Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine (Tinosorb S)**, **Ethylhexyl Triazone**, **Isoamyl p-Methoxycinnamate**, **Ethylhexyl Methoxycinnamate (Octinoxate)**, **Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (Tinosorb M)**, and **Butyl Methoxydibenzoylmethane (Avobenzone)**—providing comprehensive UVA/UVB protection (280-400 nm). Clinical studies demonstrate its efficacy in reducing actinic keratosis lesions and preventing squamous cell carcinoma in at-risk populations. The lightweight, non-greasy, fragrance-free, water-resistant (4 hours) formula with liposomal delivery enhances daily compliance and skin hydration, dispensed via an airless pump for precise dosing (0.5g per application).[1][2][3][5][9][10][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Daylong Actinica.